Advanced hormone receptor-positive/human epidermal growth factor receptor 2-positive invasive ductal carcinoma with cecal metastasis: A case report

被引:0
|
作者
Yang, Si-Yuan [1 ,2 ]
Zhang, Ji [1 ]
Yang, Zhuang-Qing [1 ,2 ]
Duan, Jia-Jun [1 ]
Zhang, Ying [3 ]
Li, Ming-Ke [4 ]
Wang, Lei [1 ]
Ye, Chun-mei [1 ]
Nie, Jian-Yun [1 ,5 ]
机构
[1] Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Dept Breast Surg 3,Affiliated Hosp 3, Kunming, Peoples R China
[2] Kunming Med Univ, Kunming, Peoples R China
[3] Third Peoples Hosp Yunnan Prov, Dept Thyroid & Breast Surg, Kunming, Peoples R China
[4] Kunming Med Univ, Dept Digest Med, Affiliated Hosp 1, Kunming, Peoples R China
[5] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Dept Breast Surg 3, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China
关键词
Breast Cancer; Gastrointestinal metastases; Cecal Metastasis; Invasive Ductal Carcinoma; Case Report; BREAST-CANCER;
D O I
10.1177/00368504231201043
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
The incidence of gastrointestinal metastases from breast cancer (BC) is low. We report a special case of Luminal B (Hormone Receptor positive [HR+]/Human Epidermal Growth Factor receptor 2-positive [HER-2+]) BC. The patient presented with asymptomatic brain metastases two years after radical surgery for modified breast cancer and developed right lower abdominal pain during relief therapy. Electronic gastroenteroscopy revealed inflammatory changes in the cecal mucosa. These changes were confirmed on pathology to be cecal metastasis from BC. The patient's condition was stabilised after treatment with an antibody-drug conjugate (ADC). For patients with BC who develop appendicitis-like symptoms after treatment for invasive ductal carcinoma of the breast, clinicians should be fully aware that the possibility of cecal metastasis needs to be considered, despite the very low probability of occurrence.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer
    Nahleh, ZA
    Jazieh, AR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (06): : 631 - 633
  • [42] Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Shay, Rebecca C.
    Diamond, Jennifer R.
    Kagihara, Jodi A.
    Sams, Sharon B.
    JOURNAL OF BREAST CANCER, 2021, 24 (01) : 106 - 116
  • [43] Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer
    Yeo, Winnie
    Luk, M. Y.
    Soong, Inda S.
    Yuen, Tony Y. S.
    Ng, T. Y.
    Mo, Frankie K. F.
    Chan, K.
    Wong, S. Y.
    Tsang, Janice
    Leung, Carmen
    Suen, Joyce J. S.
    Ngan, Roger K. C.
    HONG KONG MEDICAL JOURNAL, 2018, 24 (01) : 56 - 62
  • [44] The clinical benefit of epidermal growth factor receptor and human epidermal growth factor receptor 2 targeted agents adding to endocrine therapy in hormone receptor-positive breast cancer
    Li, Huan
    Zhai, Qing
    Yu, Bo
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S218 - S223
  • [45] Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
    Zhe-Yu Hu
    Min Yan
    Huihua Xiong
    Li Ran
    Jincai Zhong
    Ting Luo
    Tao Sun
    Ning Xie
    Liping Liu
    Xiaohong Yang
    Huawu Xiao
    Jing Li
    Binliang Liu
    Quchang Ouyang
    BMC Medicine, 21
  • [46] Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
    Hu, Zhe-Yu
    Yan, Min
    Xiong, Huihua
    Ran, Li
    Zhong, Jincai
    Luo, Ting
    Sun, Tao
    Xie, Ning
    Liu, Liping
    Yang, Xiaohong
    Xiao, Huawu
    Li, Jing
    Liu, Binliang
    Ouyang, Quchang
    BMC MEDICINE, 2023, 21 (01)
  • [47] Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Rugo, Hope S.
    Bardia, Aditya
    Marme, Frederik
    Cortes, Javier
    Schmid, Peter
    Loirat, Delphine
    Tredan, Olivier
    Ciruelos, Eva
    Dalenc, Florence
    Pardo, Patricia Gomez
    Jhaveri, Komal L.
    Delaney, Rosemary
    Fu, Olivia
    Lin, Lanjia
    Verret, Wendy
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) : 3365 - +
  • [48] Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
    Omori, Yukie
    Enatsu, Sotaro
    Cai, Zhihong
    Ishiguro, Hiroshi
    BREAST CANCER, 2019, 26 (05) : 652 - 662
  • [49] Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
    Schettini, Francesco
    Buono, Giuseppe
    Cardalesi, Cinzia
    Desideri, Isacco
    De Placido, Sabino
    Del Mastro, Lucia
    CANCER TREATMENT REVIEWS, 2016, 46 : 20 - 26
  • [50] Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
    Yukie Omori
    Sotaro Enatsu
    Zhihong Cai
    Hiroshi Ishiguro
    Breast Cancer, 2019, 26 : 652 - 662